Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · IEX Real-Time Price · USD
1.320
-0.020 (-1.49%)
Apr 25, 2024, 11:38 AM EDT - Market open

Clearside Biomedical Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202320222021202020192018201720162015
Market Capitalization
99736716413211934177184-
Market Cap Growth
-8.31%-58.91%23.85%11.02%248.26%-80.68%-3.53%--
Enterprise Value
11487541341171033147107-14
PE Ratio
-2.25-2.25-2.05436.39-7.28-3.88-0.41-3.01-7.10-
PS Ratio
12.178.8850.805.5516.7854.921142.20514.20353.61-
PB Ratio
-4.59-4.596.364.3215.1210.701.458.282.57-
P/FCF Ratio
-3.67-3.67-4.95-15.29-10.06-4.40-0.43-3.45-8.10-
P/OCF Ratio
-4.03-4.03-5.04-15.29-10.10-4.41-0.43-3.47-8.10-
EV/Sales Ratio
13.8810.5941.014.5414.8147.30100.10427.26206.68-
EV/EBITDA Ratio
-2.69-2.69-1.66242.46-6.48-3.36-0.04-2.51-4.160.81
EV/EBIT Ratio
-2.68-2.68-1.65357.24-6.42-3.34-0.04-2.50-4.150.81
EV/FCF Ratio
-4.37-4.37-4.00-12.51-8.87-3.79-0.04-2.87-4.731.03
Debt / Equity Ratio
-2.70-2.703.320.020.230.570.420.370.11-0.16
Debt / EBITDA Ratio
-1.33-1.33-1.071.22-0.11-0.21-0.12-0.14-0.29-0.34
Debt / FCF Ratio
-2.16-2.16-2.59-0.06-0.15-0.24-0.13-0.16-0.33-0.43
Quick Ratio
4.274.278.348.711.762.113.942.8115.533.90
Current Ratio
4.424.428.549.081.822.314.102.9015.593.94
Asset Turnover
0.220.220.030.930.400.0700.010.010
Return on Equity (ROE)
418.70%418.70%-153.10%1.60%-210.40%-246.60%-150.40%-131.20%-84.50%63.10%
Return on Assets (ROA)
-85.30%-85.30%-75.80%1.20%-91.60%-102.50%-108.30%-96.00%-48.00%-112.50%
Return on Capital (ROIC)
-91.71%-91.71%-66.01%-1.62%-169.51%-175.17%-246.90%-198.50%-31.80%57.49%
Earnings Yield
-32.44%-44.49%-48.87%0.23%-13.74%-25.78%-241.69%-33.24%-14.08%-
FCF Yield
-19.89%-27.27%-20.19%-6.54%-9.94%-22.70%-231.39%-28.97%-12.35%-
Buyback Yield / Dilution
-2.66%-2.66%-0.50%-28.81%-21.84%-24.20%-21.42%-93.06%-460.55%-34.53%
Total Shareholder Return
-2.66%-2.66%-0.50%-28.81%-21.84%-24.20%-21.42%-93.06%-460.55%-34.53%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).